A Study of ET-02 in Patients With Relapsed or Refractory B-cell Malignancy(NHL/ALL)

Inclusion Criteria: 1. Patients volunteer to participate in the study and sign the ICF; 2. Male or female aged≥18 years old； 3. Patient with relapsed or refractory CD19 positive B-ALL orNHL，as evidenced by 2 or more lines of prior therapy ; 4. Estimated life expectancy≥12 weeks ; 5. ECOG performance status ≤1; 6. Adequate organ function. Exclusion Criteria: 1. Patients with graft-versus-host disease (GVHD) or requiring immunosuppressive therapy； 2. History of central nervous system (CNS) involvement by malignancy； 3. Women who are pregnant or breastfeeding； 4. Any situations that may increase the risk of patients or interfere with the results of study，which judged by investigator.